Data from a suspended Phase III trial in China of Gilead’s remdesivir produced a negative result. An executive cautioned that the trial’s low enrollment meant it had insufficient statistical power to draw any conclusions, but an analyst reiterated the view that the drug’s pandemic role is overestimated.

LEAVE A REPLY

Please enter your comment!
Please enter your name here